Neuropsychiatric Drug Development Summit 2018
July 30, 2018 - August 1, 2018 - Boston MA USHanson Wade
info@hansonwade.com
Phone:16174554188
Globally it's estimated 1 in 5 people suffer from neuropsychiatric disorders. This figure, combined with drugs that are showing little or no response is making neuropsychiatric disorders a huge unmet clinical need. The neuropsychiatric drug development field has been stifled for decades by a lack of scientific progress in understanding the brain and costly and challenging clinical trials. Developed with experts at Lundbeck, Roche, GSK and 20 other leading organisations, the inaugural Neuropsychiatric Drug Development Summit will enable you to solve the challenges in bringing next generation neuropsychiatric therapeutics to market. With an emphasis on depressive disorders, this industry focused forum will allow you to explore novel targets and mechanisms of action, address factors for mitigating and eliminating risk in clinical trials and evaluate the preclinical and clinical biomarker landscape to more robustly translate preclinical results in the clinic. Join your peers at NDD to be part of the cross-industry discussion on latest developments, insights and science to elevate clinically effective neuropsychiatric therapeutic pipelines